
United States · Venture capital & private equity startup
Elm Street Ventures is a seed and early-stage venture fund based in New Haven, Connecticut, with a focus on supporting companies connected to Yale University and other Connecticut
Funding reportedLast round: Series A
Elm Street Ventures is a seed and early-stage venture fund based in New Haven, Connecticut, with a focus on supporting companies connected to Yale University and other Connecticut
intellectual property. Founded in 2006, the firm combines capital with management expertise to foster company formation, emphasizing ventures that leverage Yale research and contribute to the local entrepreneurial ecosystem. The fund invests in a variety of sectors, including life sciences, hard tech, software, and climate tech. Its interests encompass therapeutics, medical devices, diagnostics, digital health, clean technology, and information technology. Elm Street Ventures typically makes initial investments ranging from $500,000 to $1 million and may provide additional funding as companies grow. The firm has a portfolio that includes ventures like Allyx Therapeutics, Stradefy Biosciences, Desmos, and Saphlux, and it actively collaborates with companies linked to Yale and the greater New Haven area.
Funding, as reported
From Elm Street Ventures's own website: 1 on the team.
What they build
Known for
health caredigital healthbiotechnology & medical researchhard techclimate solutionsyale center for biomedical innovationinformation technology & servicesbiopharmayale research commercializationconnecticut startupsyale school of management entrepreneurshiphospital & health caresecurities and commodity contracts intermediation and brokeragegreen chemistry researchyale faculty entrepreneurshealth
Built with from their website
WordPress.orgGoogle WorkspaceViewport MetaNetwork SolutionsGoogle MeetGoogle Font APIMySQLPrimeNGMobile FriendlyjQuery
RSSSwiperFlywheelDiviWordpressjQuery MigratePHPAdobe Fonts
Add your raise, your deck and your story, and put Elm Street Ventures in front of investors. Or tell us what we have wrong.